Knowledge About Hepatitis-C Among Methadone Maintenance Treatment Patients in Israel

REFERENCES

• Aceijas, C., Rhodes T. (2007). Global estimates of prevalence of HCV infection among injecting drug users. International Journal of Drug Policy, 18:352–358.
   PubMed Web of Science ®Google Scholar
• Astone-Twerell, J. M., Strauss, S. M., Hagan, H., Des Jarlais, D. C. (2005). Providing support to drug users infected with hepatitis C: the role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions, 3:33–46.
   Google Scholar
• Backmund, M., Meyer, K., Von Zielonka, M., Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34:188–193.
   PubMed Web of Science ®Google Scholar
• Birkhead, G. S., Klein, S. J., Candelas, A. R., O'Connell, D. A., Rothman, J. R., Feldman, I. S., (2007). Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. International Journal of Drug Policy, 18:417–425.
   PubMed Web of Science ®Google Scholar
• Breslow, N. E., Day, N. E. (1980). Statistical methods in cancer research. Volume I: the analysis of case-control studies. Lyon: IARC Scientific Publications No 32.
   Google Scholar
• Brown, R. S. Jr., Gaglio, P. J. (2003). Scope of worldwide hepatitis C problem. Liver Transplantation, 9:S10–S13.
   PubMed Web of Science ®Google Scholar
• Carey, J., Perlman, D. C., Friedmann, P., Kaplan, W. M., Nugent, A., Deutscher, M., (2005). Knowledge of hepatitis among active drug injectors at a syringe exchange program. Journal of Substance Abuse Treatment, 29:47–53.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, Health People 2010- Immunization and Infectious Diseases. (2000). Retrieved April 6, 2008, from http://www.healthypeople.gov/document/html/volume1/14immunization.htm.
   Google Scholar
• Dhopesh, V. P., Taylor, K. R., Burke, W. M. (2000). Survey of hepatitis B and C in addiction treatment unit. American Journal of Drug and Alcohol Abuse, 26:703–707.
   PubMed Web of Science ®Google Scholar
• Doab, A., Treloar, C., Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(5 Suppl.):S313–S320.
   Google Scholar
• Dore, G. J., Law, M., MacDonald, M., Kaldor, J. M. (2003). Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 26:171–184.
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban, S., Poynard, T., Sulkowski, M. S., Wong, J. B. (2007). Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. Journal of Viral Hepatalogy, 14:107–115.
   PubMed Web of Science ®Google Scholar
• Deutsch, M., Hadziyannis, S. J. (2008). Old and emerging therapies in chronic hepatitis C: an update. Journal of Viral Hepatitis, 15:2–11.
   PubMed Web of Science ®Google Scholar
• D'Souza, R. F., Glynn, M. J., Alstead, E., Osonayo, C., Foster, G. R. (2004). Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. QJM, 97:331–336.
   PubMed Web of Science ®Google Scholar
• Edlin, B. R., Kresina, T. F., Raymond, D. B., Carden, M. R., Gourevitch, M. N., Rich, J. D., (2005). Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases, 40(5 Suppl.):S276–S285.
   Google Scholar
• Fischer, B., Kalousek, K., Rehm, J., Powis, J., Krajden, M., Reimer, J. (2006). Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?? Canadian Journal of Public Health, 97:485–488.
   PubMed Web of Science ®Google Scholar
• Fishbein, D. A., Lo, Y., Reinus, J. F., Gourevitch, M. N., Klein, R. S. (2004). Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndromes, 37:1367–1375.
   PubMed Web of Science ®Google Scholar
• Fisher, J. D., Fisher, W. A. (1992). Changing AIDS-risk behavior. Psychological Bulletin, 111:455–474.
   PubMed Web of Science ®Google Scholar
• Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347:975–982.
   PubMed Web of Science ®Google Scholar
• Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showler, G., (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93:141–147.
   PubMed Web of Science ®Google Scholar
• Gyarmathy, V. A., Neaigus, A., Miller, M., Friedman, S. R., Des Jarlais, D. C. (2002). Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. Journal of Acquired Immune Deficiency Syndromes, 30:448–456.
   PubMed Web of Science ®Google Scholar
• Hagan, H., Strauss, S. M., Astone, J. M., Des Jarlais, D. C. (2005). Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clinical Infectious Diseases, 40(5 Suppl.):S297–S303.
   Google Scholar
• Hagedorn, H., Dieperink, E., Dingmann, D., Durfee, J., Ho, S. B., Isenhart, C., (2007). Integrating hepatitis prevention services into a substance use disorder clinic. Journal of Substance Abuse Treatment, 32:391–398.
   PubMedGoogle Scholar
• Hallinan, R., Byrne, A., Agho, K., Dore, G. J. (2007). Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence, 88:49–53.
   PubMed Web of Science ®Google Scholar
• Hallinan, R., Byrne, A., Amin, J., Dore, G. J. (2005). Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of Gastroenterology and Hepatology, 20:1082–1086.
   PubMed Web of Science ®Google Scholar
• Health Canada, Hepatitis C — Final Report. Angus Reid Group. (2000). Retrieved April 6, 2008, from http://www.phac-aspc.gc.ca/hepc/pubs/fr-rf00/pdf/careDiscSurvey.pdf.
   Google Scholar
• Heimer, R., Clair, S., Grau, L. E., Bluthenthal, R. N., Marshall, P. A., Singer, M. (2002). Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97:1277–1287.
   PubMed Web of Science ®Google Scholar
• Hu, S. W., Lai, H. R., Liao, P. H. (2004). Comparing dental students' knowledge of and attitudes toward hepatitis B virus-, hepatitis C virus-, and HIV-infected patients in Taiwan. AIDS Patient Care and STDs, 18:587–593.
   PubMed Web of Science ®Google Scholar
• Khuwaja, A. K., Qureshi, R., Fatmi, Z. (2002). Knowledge about hepatitis B and C among patients attending family medicine clinics in Karachi. Eastern Mediterranean Health Journal, 8:787–793.
   PubMedGoogle Scholar
• Kwiatkowski, C. F., Fortuin Corsi, K., Booth, R. E. (2002). The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction, 97:1289–1294.
   PubMed Web of Science ®Google Scholar
• Law, M. G., Dore, G. J., Bath, N., Thompson, S., Crofts, N., Dolan, K., (2003). Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 32:717–724.
   PubMed Web of Science ®Google Scholar
• Litwin, A. H., Soloway, I., Gourevitch, M. N. (2005). Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clinical Infectious Diseases, 40(5 Suppl.):S339–S345.
   Google Scholar
• Loguercio, C., Di Pierro, M., Di Marino, M. P., Federico, A., Disalvo, D., Crafa, E., (2000). Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol and Alcoholism, 35:296–301.
   PubMed Web of Science ®Google Scholar
• Mauss, S., Berger, F., Goelz, J., Jacob, B., Schmutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40:120–124.
   PubMed Web of Science ®Google Scholar
• McCarthy, J. J., Flynn, N. (2001). Hepatitis C in methadone maintenance patients: prevalence and public policy implications. Journal of Addictive Diseases, 20:19–31.
   PubMed Web of Science ®Google Scholar
• Mehta, S. H., Thomas, D. L., Sulkowski, M. S., Safaein, M., Vlahov, D., Strathdee, S. A. (2005). A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS, 19(3 Suppl.):S179–S189.
   PubMedGoogle Scholar
• Memon, M. I., Memon, M. A. (2002). Hepatitis C: an epidemiological review. Journal of Viral Hepatitis, 9:84–100.
   PubMed Web of Science ®Google Scholar
• Morrow, K., Costello, T. (2004). HIV, STD and hepatitis prevention among women in methadone maintenance: a qualitative and quantitative needs assessment. AIDS Care, 16:426–433.
   PubMed Web of Science ®Google Scholar
• Munoz-Plaza, C. E., Strauss, S. M., Astone, J. M., Des Jarlais, D. C., Hagan, H. (2004). Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: client and staff perspectives. Journal of Drug Issues, 34:861–878.
   Web of Science ®Google Scholar
• Munoz-Plaza, C. E., Strauss, S. M., Astone-Twerwll, J. M., Des Jarlais, D. C., Hagan, H. (2006). Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs. Journal of Psychoactive Drugs, 38:233–241.
   PubMed Web of Science ®Google Scholar
• Novick, D. M. (2000). The impact of hepatitis C virus infection on methadone maintenance treatment. The Mount Sinai Journal of Medicine, 67:437–443.
   PubMedGoogle Scholar
• Ompad, D. C., Fuller, C. M., Vlahov, D., Thomas, D., Strathdee, S. A. (2002). Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clinical Infectious Diseases, 35:783–788.
   PubMed Web of Science ®Google Scholar
• Peles, E., Schreiber, S., Adelson, M. (2006). Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug and Alcohol Dependence, 82:211–217.
   PubMed Web of Science ®Google Scholar
• Quaglio, G., Lugoboni, F., Pajusco, B., Sarti, M., Talamini, G., Lechi, A., (2003). Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clinical Infectious Diseases, 37:33–40.
   PubMedGoogle Scholar
• Reynolds, G. L., Fisher, D. G., Jaffe, A., Edwards, J. (2006). Follow-up for medical care among drug users with hepatitis C. Evaluation & the Health Professions, 29:355–366.
   PubMed Web of Science ®Google Scholar
• Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldberg, D., Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiology and Infection, 129:577–585.
   PubMed Web of Science ®Google Scholar
• Sastre, M. T., Monsirmen, S., Morin, G., Presutto, E., Seguela, L., Vinel, J.-P., (2006). Changes in French people's misconceptions about hepatitis C, 1997–2003. Preventive Medicine, 42:150–153.
   PubMedGoogle Scholar
• Schaefer, M., Heinz, A., Backmund, M. (2004). Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?? Addiction, 99:1167–1175.
   PubMed Web of Science ®Google Scholar
• Scheinmann, R., Hagan, H., Lelutiu-Weinberger, C., Stern, R., Des Jarlais, D. C., Flom, P. L., (2007). Non-injection drug use and Hepatitis C Virus: a systematic review. Drug and Alcohol Dependence, 89:1–12.
   PubMed Web of Science ®Google Scholar
• Schiff, M., Levit, S., Moreno, R. C. (2007). Retention and illicit drug use among methadone patients in Israel: a gender comparison. Addictive Behaviors, 32:2108–2019.
   PubMed Web of Science ®Google Scholar
• Seeff, L. B., Hoofnagle, J. H. (2003). Appendix: the National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clinics in Liver Disease, 7:261–287.
   PubMedGoogle Scholar
• Sergio, N., Salvatore, T., Gaetano, B., Davide, P., Claudio, I., Massimo, L., (2007). Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin. Journal of Gastroenterology and Hepatology, 22:74–79.
   PubMedGoogle Scholar
• Shackman, B. R., Teixeira, P. A., Beeder, A. B. (2007). Offers of hepatitis C care do not lead to treatment. Journal of Urban Health, 84:455–458.
   PubMedGoogle Scholar
• Shepard, C. W., Finelli, L., Alter, M. J. (2005). Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases, 5:558–567.
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Maksad, J., Clarke, J. (2001). Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence, 61:211–215.
   PubMed Web of Science ®Google Scholar
• Stephenson, J. (2001). Former addicts face barriers to treatment for HCV. JAMA, 285:1003–1005.
   PubMed Web of Science ®Google Scholar
• Stoové, M. A., Gifford, S. M., Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 77:81–86.
   PubMed Web of Science ®Google Scholar
• Strathdee, S. A., Latka, M., Campbell, J., O'Driscoll, P. T., Golub, E. T., Kapadia, F., (2005). Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(5 Suppl.):S304–S312.
   Google Scholar
• Strauss, S. M., Astone, J. M., Hagan, H., Des Jarlais, D. C. (2004a). The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. Journal of Urban Health, 81:38–47.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Astone, J. M., Jarlais, D. D., Hagan, H. (2004b). A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence, 73:227–236.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Astone, J. M., Munoz-Plaza, C., Hagan, H., Des Jarlais, D. C. (2005). Residential drug treatment programs as venues for HCV pharmacological treatment: client and staff perspectives. Substance Use and Misuse, 40:1811–1829.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Astone-Twerell, J. M., Munoz-Plaza, C., Des Jarlais, D. C., Gwadz, M., Hagan, H., (2006). Hepatitis C knowledge among staff in U.S. drug treatment programs. Journal of Drug Education, 36:141–158.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Astone-Twerell, J., Munoz-Plaza, C. E., Des Jarlais, D. C., Gwadz, M., Hagan, H., (2007). Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research, 7:39.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Falkin, G. P., Vassilev, Z., Des Jarlais, D. C., Astone, J. (2002). A nationwide survey of hepatitis C services provided by drug treatment programs. Journal of Substance Abuse Treatment, 22:55–62.
   PubMed Web of Science ®Google Scholar
• Sulkowski, M. S., Thomas, D. L. (2005). Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clinical Infectious Diseases, 40(5 Suppl.):S263–S269.
   Google Scholar
• Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence, 67:117–123.
   PubMed Web of Science ®Google Scholar
• Tortu, S., Neaigus, A., McMahon, J., Hagen, D. (2001). Hepatitis C among noninjecting drug users: a report. Substance Use & Misuse, 36:523–534.
   PubMed Web of Science ®Google Scholar
• van den Berg, C. H., Smit, C., Bakker, M., Geskus, R. B., Berkhout, B., Jurriaans, S., (2007). Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology, 22:183–193.
   PubMed Web of Science ®Google Scholar
• Vidal-Trécan, G., Coste, J., Varescon-Pousson, I., Christoforov, B., Boissonnas, A. (2000). HCV status knowledge and risk behaviours amongst intravenous drug users. European Journal of Epidemiology, 16:439–445.
   PubMed Web of Science ®Google Scholar
• Walley, A. Y., White, M. C., Kushel, M. B., Song, Y. S., Tulsky, J. P. (2005). Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 28:181–1877.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Sheridan, J., Lovell, S., Farrell, M., Strang, J. (2000). National survey of hepatitis testing and vaccination services provided by drug services in England and Wales. European Journal of Clinical Microbiology & Infectious Diseases, 19:823–828.
   PubMed Web of Science ®Google Scholar